NeuroCycle Therapeutics, Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2016

Location

Cambridge MA US

Primary Industry

Biotechnology

About

Founded in 2016 and based in Massachusetts, US, NeuroCycle Therapeutics, Inc. develops treatments for people with epilepsy and neuropathic pain. The firm was acquired by Engrail Therapeutics, Inc. in February 2021. NeuroCycle Therapeutics, Inc. focuses on sub-type selective GABA-A modulation with NCT10004 as the treatment for genetic epilepsy syndromes. The firm provides treatments for the itch, pain, and certain refractory forms of pediatric epilepsy. The acquisition will strengthen Engrail's initiation of clinical trials with multiple assets in 2021.

Current Investors

Engrail Therapeutics, Inc.

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Pharmaceutical Research & Development

Website

www.neurocycletherapeutics.com

Company Stage

Add-on

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.